Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-03-2014 | Genetics

Predictive value of VEGF A and VEGFR2 polymorphisms in the response to intravitreal ranibizumab treatment for wet AMD

Authors: Fernando Cruz-Gonzalez, Lucía Cabrillo-Estévez, Gloria López-Valverde, Clara Cieza-Borrella, Emiliano Hernández-Galilea, Rogelio González-Sarmiento

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 3/2014

Abstract

Background

To determine whether gene polymorphisms of the vascular endothelial growth factor A (VEGF A) and its receptor (VEGFR) influence the response to a variable-dosing treatment regimen with ranibizumab for age-related macular degeneration.

Methods

This prospective cohort study included 94 patients (94 eyes) with exudative age-related macular degeneration (AMD) treated with ranibizumab. Patients underwent a 1-year treatment as in the Study of Ranibizumab in Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (SUSTAIN). Injections were administered monthly during 3 months to all the patients diagnosed of neovascular AMD; reinjections were made when a patient lost 5 letters on the Early Treatment Diabetic Retinopathy Study chart or gained 100 μm in central subfield retinal thickness measured by OCT. Genotypes (VEGF A (rs 699947, rs833061) and VEGFR (rs 2071559)) were analyzed using TaqMan probes. Best-corrected visual acuity (BCVA), subjective improvement, and macular thickness measured with OCT values were compared with VEGF A and VEGFR genotypes. Multiple regression analysis was used to assess the statistical significance.

Results

We found statistically significant differences in allelic distribution of VEGF A rs833061 polymorphism in relation with the response to intravitreal ranibizumab regarding to visual acuity improvement [p = 0,.34; OR: 1.619 (1.098–2.386)]. Patients carrying “protector” genotype CC had higher probability of best corrected visual acuity improvement. When we analyzed VEGF A rs699947 polymorphism we found that patients expressing AA genotype had a higher chance of increasing their best corrected visual acuity [p:0,022; OR 1,532 (1,015–2,313)]. We did not find statistically significant differences reagarding VEGFR rs2071559 polymorphism and treatment response.

Conclusions

Polymorphisms of VEGF A seem to influence the different response to antiangiogenic treatment in patients with AMD in our population, although further investigation is needed to know the mechanisms of this relationship.

Friedman DS, O’Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, Kempen J (2004) Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 122:564–572PubMedCrossRef

Montezuma SR, Sobrin L, Seddon JM (2007) Review of genetics in age related macular degeneration. Semin Ophthalmol 22:229–240PubMedCrossRef

Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676PubMedCrossRef

Hubschman JP, Reddy S, Schwartz SD (2009) Age-related macular degeneration: experimental and emerging treatments. Clin Ophthalmol 3:167–174PubMedCentralPubMedCrossRef

Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K (2000) Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 60:203–212PubMed

Grisanti S, Tatar O (2008) The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration. Prog Retin Eye Res 27:372–390PubMedCrossRef

Zeng G, Gao L, Birkle S, Yu RK (2000) Suppression of ganglioside GD3 expression in a rat F-11 tumor cell line reduces tumor growth, angiogenesis, and vascular endothelial growth factor production. Cancer Res 60:6670–6676PubMed

Churchill AJ, Carter JG, Lovell HC, Ramsden C, Turner SJ, Yeung A, Escardo J, Atan D (2006) VEGF polymorphisms are associated with neovascular age-related macular degeneration. Hum Mol Genet 15:2955–2961PubMedCrossRef

Haines JL, Schnetz-Boutaud N, Schmidt S, Scott WK, Agarwal A, Postel EA, Olson L, Kenealy SJ, Hauser M, Gilbert JR, Pericak-Vance MA (2006) Functional candidate genes in age-related macular degeneration: significant association with VEGF, VLDLR, and LRP6. Invest Ophthalmol Vis Sci 47:329–335PubMedCrossRef

10.

Lin JM, Wan L, Tsai YY, Lin HJ, Tsai Y, Lee CC, Tsai CH, Tseng SH, Tsai FJ (2008) Vascular endothelial growth factor gene polymorphisms in age-related macular degeneration. Am J Ophthalmol 145:1045–1051PubMedCrossRef

11.

Boekhoorn SS, Isaacs A, Uitterlinden AG, van Duijn CM, Hofman A, de Jong PT, Vingerling JR (2008) Polymorphisms in the vascular endothelial growth factor gene and risk of age-related macular degeneration: the Rotterdam Study. Ophthalmology 115:1899–1903PubMedCrossRef

12.

Janik-Papis K, Zaras M, Krzyzanowska A, Wozniak K, Blasiak J, Szaflik J, Szaflik JP (2009) Association between vascular endothelial growth factor gene polymorphisms and age-related macular degeneration in a Polish population. Exp Mol Pathol 87:234–238PubMedCrossRef

13.

Qu Y, Dai H, Zhou F, Zhang X, Xu X, Bi H, Pan X, Wang H, Jiang H, Yin N, Dang G (2011) Vascular endothelial growth factor gene polymorphisms and risk of neovascular age-related macular degeneration in a Chinese cohort. Ophthalmic Res 45:142–148PubMedCrossRef

14.

Richardson AJ, Islam FM, Guymer RH, Cain M, Baird PN (2007) A tag-single nucleotide polymorphisms approach to the vascular endothelial growth factor-A gene in age-related macular degeneration. Mol Vis 13:2148–2152PubMed

15.

Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: 2-year results of the ANCHOR study. Ophthalmology 116(57–65):e55

16.

Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431PubMedCrossRef

17.

Zachary I (2005) Neuroprotective role of vascular endothelial growth factor: signalling mechanisms, biological function, and therapeutic potential. Neurosignals 14:207–221PubMedCrossRef

18.

Mitchell P, Korobelnik JF, Lanzetta P, Holz FG, Prunte C, Schmidt-Erfurth U, Tano Y, Wolf S (2010) Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 94:2–13PubMedCrossRef

19.

Galan A, Ferlin A, Caretti L, Buson G, Sato G, Frigo AC, Foresta C (2010) Association of age-related macular degeneration with polymorphisms in vascular endothelial growth factor and its receptor. Ophthalmology 117:1769–1774PubMedCrossRef

20.

Cruz-González F, Cieza-Borrella C, Cabrillo-Estévez L, Cañete-Campos C, Escudero-Domínguez F, González-Sarmiento R (2013) VEGF A (rs699947 and rs833061) and VEGFR2 (rs2071559) gene polymorphisms are not associated with AMD susceptibility in a Spanish population. R Curr Eye Res 38(12):1274–1277CrossRef

21.

Lazzeri S, Orlandi P, Figus M, Fioravanti A, Cascio E, Di Desidero T, Agosta E, Canu B, Sartini MS, Danesi R, Nardi M, Bocci G (2012) The rs2071559 AA VEGFR-2 genotype frequency is significantly lower in neovascular age-related macular degeneration patients. Sci World J 2012:420190CrossRef

22.

Fang AM, Lee AY, Kulkarni M, Osborn MP, Brantley MA Jr (2009) Polymorphisms in the VEGFA and VEGFR-2 genes and neovascular age-related macular degeneration. Mol Vis 15:2710–2719PubMedCentralPubMed

23.

Kloeckener-Gruissem B, Barthelmes D, Labs S, Schindler C, Kurz-Levin M, Michels S, Fleischhauer J, Berger W, Sutter F, Menghini M (2011) Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD. Invest Ophthalmol Vis Sci 52:4694–4702PubMedCrossRef

24.

McKibbin M, Ali M, Bansal S, Baxter PD, West K, Williams G, Cassidy F, Inglehearn CF (2011) CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration. Br J Ophthalmol 96(2):208–212PubMedCrossRef

25.

Lazzeri S, Figus M, Orlandi P, Fioravanti A, Di Desidero T, Agosta E, Sartini MS, Posarelli C, Nardi M, Danesi R, Bocci G (2013) VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration. Pharmacogenomics 14(6):623–630PubMedCrossRef

26.

Smailhodzic D, Muether PS, Chen J, Kwestro A, Zhang AY, Omar A, Van de Ven JP, Keunen JE, Kirchhof B, Hoyng CB, Klevering BJ, Koenekoop RK, Fauser S, den Hollander AI (2012) Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration. Ophthalmology 119(11):2304–2311PubMedCrossRef

27.

Chang W, Noh DH, Sagong M, Kim IT (2013) Pharmacogenetic association with early response to intravitreal ranibizumab for age-related macular degeneration in a Korean population. Mol Vis 19:702–709PubMedCentralPubMed

28.

Tsuchihashi T, Mori K, Horie-Inoue K, Gehlbach PL, Kabasawa S, Takita H, Ueyama K, Okazaki Y, InoueS AT, Katayama S, Yoneya S (2011) Complement factor H and high-temperature requirement A-1 genotypes and treatment response of age-related macular degeneration. Ophthalmology 118:93–100PubMedCrossRef

29.

Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW (2003) Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 63:812–816PubMed

30.

Boltz A, Ruiz M, Jonas JB, Tao Y, Rensch F, Weger M, Garhöfer G, Frantal S, El-Shabrawi Y, Schmetterer L (2012) Role of vascular endothelial growth factor polymorphisms in the treatment success in patients with wet age-related macular degeneration. Ophthalmology 119(8):1615–1620PubMedCrossRef

31.

Schmidt S, Hauser MA, Scott WK, Postel EA, Agarwal A, Gallins P, Wong F, Chen YS, Spencer K, Schnetz-Boutaud N, Haines JL, Pericak-Vance MA (2006) Cigarette smoking strongly modifies the association of LOC387715 and age-related macular degeneration. Am J Hum Genet 78:852–864PubMedCentralPubMedCrossRef

32.

de Santa C, Pau E, Arias FC, Caso Pelaez E, Munoz Molina GM, Sanchez Hernandez I, Muguruza Trueba I, Moreno Balsalobre R, Sacristan Lopez S, Gomez Pinillos A, del Val Toledo Lobo M (2009) Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer. Cancer 115:1701–1712CrossRef

33.

Forsti A, Jin Q, Altieri A, Johansson R, Wagner K, Enquist K, Grzybowska E, Pamula J, Pekala W, Hallmans G, Lenner P, Hemminki K (2007) Polymorphisms in the KDR and POSTN genes: association with breast cancer susceptibility and prognosis. Breast Cancer Res Treat 101:83–93PubMedCrossRef

34.

Pabst S, Karpushova A, Diaz-Lacava A, Herms S, Walier M, Zimmer S, Cichon S, Nickenig G, Nöthen MM, Wienker TF, Grohé C (2010) VEGF gene haplotypes are associated with sarcoidosis. Chest 137:156–163PubMedCrossRef

35.

Wang Y, Zheng Y, Zhang W, Yu H, Lou K, Zhang Y, Qin Q, Zhao B, Yang Y, Hui R (2007) Polymorphisms of KDR gene are associated with coronary heart disease. J Am Coll Cardiol 50:760–767PubMedCrossRef

Title: Predictive value of VEGF A and VEGFR2 polymorphisms in the response to intravitreal ranibizumab treatment for wet AMD
Authors: Fernando Cruz-Gonzalez
Lucía Cabrillo-Estévez
Gloria López-Valverde
Clara Cieza-Borrella
Emiliano Hernández-Galilea
Rogelio González-Sarmiento
Publication date: 01-03-2014
Publisher: Springer Berlin Heidelberg
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 3/2014
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-014-2585-7

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Predictive value of VEGF A and VEGFR2 polymorphisms in the response to intravitreal ranibizumab treatment for wet AMD

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2014

Clinical features of IgG4-related dacryoadenitis

The macular pigment optical density spatial profile and increasing age

Comprehensive approach to ocular consequences of Stevens Johnson Syndrome - the aftermath of a systemic condition

The use of heterochromatic flicker photometry to determine macular pigment optical density in a healthy Australian population

The price for reduced light toxicity: Do endoilluminator spectral filters decrease color contrast during Brilliant Blue G–assisted chromovitrectomy?

Higher optic nerve sheath diameters are associated with lower ocular blood flow velocities in glaucoma patients